DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

TERMINATED

Identifier: CI-TRIAL-00090135
Entity page: /trial/NCT04752163 ↗
Edges: 20

Neighbours: 5 cancers11 drugs
Drawn: 16 of 16 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia condition of …CONDITION_OFderived9 of 9
← condition of	Acute Lymphoblastic Leukemia registry condition “Recurrent Acute Lymphoblastic Leukemia” mapped CURATED_BROADER	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Acute Lymphoblastic Leukemia registry condition “Refractory Acute Lymphoblastic Leukemia” mapped CURATED_BROADER

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia intervention of …INTERVENTION_OFderived11 of 11
← intervention of	Azacitidinesmall molecule registry intervention “Azacitidine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cyclophosphamidesmall molecule registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cytarabinesmall molecule registry intervention “Cytarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dexamethasonesmall molecule registry intervention “Dexamethasone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Filgrastimother registry intervention “Filgrastim” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Leucovorinsmall molecule registry intervention “Leucovorin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Methotrexatesmall molecule registry intervention “Methotrexate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Prednisonesmall molecule registry intervention “Prednisone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rituximabmonoclonal antibody registry intervention “Rituximab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Venetoclaxsmall molecule registry intervention “Venetoclax” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vincristinesmall molecule registry intervention “Vincristine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia intervention of …INTERVENTION_OFderived11 of 11

← intervention of

Azacitidinesmall molecule

registry intervention “Azacitidine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Cyclophosphamidesmall molecule

registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS

—